logo
Mysterious change in Pacific to 'lock' US in megadrought that'll send food prices soaring for DECADES

Mysterious change in Pacific to 'lock' US in megadrought that'll send food prices soaring for DECADES

Daily Mail​a day ago
A troubling shift in the Pacific Ocean has trapped the US in a megadrought, with scientists warning it could drive devastating wildfires, food shortages, and soaring prices for decades.
Researchers from the University of Colorado Boulder have found that a natural Pacific climate cycle, the Pacific Decadal Oscillation (PDO), is stuck in a 'negative' phase, bringing dangerously dry conditions to much of the US West Coast.
The PDO acts like a slow-moving seesaw, swinging ocean surface temperatures between warmer and cooler phases every 20 to 30 years.
Its current negative phase cools waters along North America's west coast and warms the central Pacific, a combination that disrupts rainfall patterns, intensifies drought, and fuels heat.
Unlike regular droughts that can last months or a few years, a megadrought can linger for decades or more, with extreme dryness and little rainfall drying up the soil, rivers, and local reservoirs.
The current megadrought, ongoing since around 2000, has impacted Southwestern states like California, Nevada, Arizona, Utah, New Mexico, Colorado, and parts of Oregon, Nebraska, Kansas, and Oklahoma.
The extreme dryness has already lasted more than two decades, but researchers discovered the PDO shows no signs of changing to a 'positive' phase of wet weather because of a new factor impacting the planet: man-made greenhouse emissions.
The extreme conditions in the Southwest are predicted to bring even more devastating fires to several states before the end of 2025 and for years to come.
California, the nation's top agricultural state, produces over a third of America's vegetables and two-thirds of its fruits and nuts, including almonds, lettuce, and tomatoes.
Severe water shortages since 2021 have forced farmers to leave hundreds of thousands of acres unplanted. Arizona, Nevada, and Utah, key dairy and meat producers, are also facing shrinking herds and reduced milk production.
All of this leads to small crop yields, higher food prices, livestock struggling to provide enough milk for cheese and butter, and food insecurity for those unable to afford their everyday groceries.
The study's findings, published in the journal Nature, challenged the long-held belief that the PDO's regular shifts were only driven by natural processes, such as ocean currents and atmospheric patterns.
This new research showed that human-induced changes to the planet now account for more than half (53%) of the variations in the PDO dating back to 1950.
Researchers found that the impact of man-made climate change has altered the PDO, essentially locking it into a permanent 'negative' trend since the 1980s, gradually drying out these key regions for food production.
Human activities, particularly the emission of greenhouse gases from burning fossil fuels in cars, factories, and power plants, have trapped heat and warmed the central Pacific more than what naturally occurs every few decades.
The dire conditions have also fueled massive wildfires throughout several states from Texas to California, including January's blaze in Los Angeles that destroyed more than 50,000 acres of land and over 16,000 homes.
Firefighters have been battling more wildfires throughout the western US as dry conditions have lingered for decades
Specifically, high levels of aerosols in the atmosphere before the 1980s fueled a 'positive phase' along the West Coast.
During this time, the central Pacific was cooler, and the waters along North America's coast were warmer, often bringing wetter weather to the western US.
Aerosols, tiny particles coming from industrial activities like burning coal and manufacturing from the 50s to the 80s, are still a form of human pollution, but they reflect sunlight into space, cooling the Pacific.
As the world cut back on this form of pollution, other emissions like carbon dioxide drastically warmed the planet and locked the PDO into a 'negative' trend of dry weather.
Study author Jeremy Klavans from the University of Colorado said: 'Climate models taken at face value didn't have the answer for us.'
'They told us it was bad luck,' he told New Scientist.
To prove that the phenomenon was man-made and not an unusually long cycle of natural dryness, the scientists used a massive collection of 572 climate model simulations on the PDO.
These simulations included various external factors like greenhouse gas emissions, aerosol pollution, volcanic eruptions, and solar changes, covering the period from 1950 to 2014.
Researchers were even able to adjust for the impact of El Niño and La Niña events, which can affect the PDO over shorter windows of time.
The results of these simulations continued to show that rising greenhouse gas emissions, combined with less aerosol pollution, could keep wetter weather away from the West Coast far beyond what naturally occurs without climate change.
Pedro DiNezio, also from the University of Colorado, said: 'We looked into the future, and models make it persist for at least a few more decades.'
'As long as the northern hemisphere continues to warm, the PDO will be stuck in this negative phase,' the study author warned.
The ongoing drought could lead to more devastating fires along the West Coast later this year.
Meteorologists have forecasted that California could see up to 1.5 million acres of land burn before the end of 2025.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The pioneering therapy that could roll back the rigours of ageing
The pioneering therapy that could roll back the rigours of ageing

Telegraph

time2 hours ago

  • Telegraph

The pioneering therapy that could roll back the rigours of ageing

The clock could be turned back on ageing with a groundbreaking new therapy that aims to recharge cells with 'batteries' from the placenta of newborns. Israel-based Minovia Therapeutics is the first company in the world to start testing mitochondrial transplantation in humans, which could treat incurable diseases and keep bodies younger for longer. Mitochondria are tiny compartments within cells that act like batteries, supplying the cell with the energy it needs to function. In ageing and certain diseases, the mitochondria stop working efficiently, starving the cells of energy, similar to the batteries running down in a machine. But scientists have now shown that it is possible to 'augment' cells with supercharged mitochondria from the placenta. Minovia has already completed clinical trials of the new therapy for patients with Pearson's Syndrome - a mitochondrial disease - and is planning to trial the treatment in elderly people next year. Dr Natalie Yivgi-Ohana, CEO and co-founder of Minovia, said: 'It's actually a very natural process for cells to take up mitochondria when they come in contact with them, but it was usually only one in 1000 cells that would do it. 'In the past 13 years, we've developed a method to maximise cellular take up without harming the cells or the mitochondria, so now more than 50 per cent of cells take up a significant amount of mitochondria. 'We take it from the youngest and healthiest organ, which is the placenta and which is full of super mitochondria and yet it's normally thrown away like garbage. We could find it to be the fountain of youth.' To make the therapy, scientists take the mitochondria from a healthy donated placenta and mix them with blood stem cells, which are then infused back into the patient's bloodstream. Not only do the super mitochondria help to produce more energy in cells, but they also reactivate natural quality control functions inside cells, which keep failing mitochondria at bay. So over time, the level of the body's healthy mitochondria also goes up. Last month, the company released phase 2 results for Pearson Syndrome, which can cause a range of problems in children, including failure to thrive, diabetes and neurological issues. There are currently no approved therapies for the condition, and care is only palliative, with patients dying during childhood. But the new therapy has led to marked improvements. 'Severe energy failure' 'These were all paediatric patients and they suffer severe energy failure, so they are not growing,' added Dr Yivgi-Ohana. 'It took a few months, but we have started observing improvement in their energy and less fatigue, more waking hours. We observed improvement in renal function, improvement in appetite, in growth.' Now the company is turning its attention towards ageing, and is hoping that growing older may one day be seen as a treatable disease. The company is planning to start trials of the treatment for elderly people in Israel next year and is developing biomarkers so they can test whether older people are experiencing mitochondrial dysfunction. It could even help diseases of ageing, such as Parkinson's, which is strongly linked to mitochondrial dysfunction. 'Significant in almost every disease' 'We are all going to suffer mitochondrial disease as we age,' added Dr Yivgi-Ohana. 'Ageing is not considered a disease, but if we have a way to demonstrate that actually, as we age, we become mitochondrially dysfunctional, then that would be the trigger to propose a treatment. 'We want to start next year treating elderly people with mitochondrial dysfunction in longevity clinics and demonstrate that it really helps. ' She added: 'The scalability in terms of the mitochondria is unlimited, there are no limitations of placentas and the amount of mitochondria that we can harvest and cryopreserve.' 'Mitochondria are such powerful organelles, and they can transfer between cells, so their sensing and their information transfer is so significant in almost every disease that you will look at.'

Experimental drug eliminates aggressive breast, skin cancer in small trial
Experimental drug eliminates aggressive breast, skin cancer in small trial

Medical News Today

time10 hours ago

  • Medical News Today

Experimental drug eliminates aggressive breast, skin cancer in small trial

Scientists have developed a new cancer drug that can be injected directly into tumors. The treatment, an enhanced CD40 agonist, was successful in its first trial of 12 human participants. Six people in the group saw their tumors shrink, while two participants saw their cancer go completely into remission. The National Institutes of Health project that doctors will diagnose at least 2 million new cancer cases and that 600,000 people will die from cancer in 2025 in the United improving cancer death rates, this prediction highlights the need to continue developing more effective treatments. Researchers from Rockefeller University made headway in this area with the completion of their human phase 1 study. They tested a new CD40 antibody drug, 2141-V11, designed to shrink tumors and reduce side new drug had promising results, shrinking tumors in half the patients and completely eliminating cancer in two cases, while not causing serious side effects. The study appears in the journal Cancer Cell.A new approach to cancer immunotherapyMany cancer treatments exist, and sometimes treatment can be as simple as removing the tumor or lesion for localized cancers. In cases where the cancer is metastatic and has spread, more aggressive treatments are necessary. Some types of more aggressive cancer treatments include: radiation therapychemotherapyhormone American Cancer Society describes immunotherapy as a 'treatment that uses the body's immune system, usually your own, to attack cancer.' There are several types of immunotherapy, such as immune checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Researchers in the new study focused on immunotherapy — specifically, the CD40 agonist antibody drug class, a type of monoclonal antibody treatment. It works by activating the CD40 receptor and causing an immune system response. According to the study authors, research on CD40 has not been successful in human trials in the past and has caused serious side effects. This led the scientists to create an engineered form of CD40 called 2141-V11. The drug was designed to improve the issues with CD40 and reduce systemic inflammation and liver toxicity. The scientists also decided to inject the treatment directly into the tumor instead of administering it intravenously. For the human study, the researchers recruited 12 participants, and everyone in the group had metastatic cancers including melanoma and breast cancer. The participants ranged from ages 42 to participants received injections of 2141-V11 into their tumors every 3 weeks, with an increased dosage each results with limited toxicityThroughout the 2141-V11 treatments, the researchers monitored the side effects and bloodwork of the participants. They were especially concerned with the participants' platelet count and liver enzymes since these would indicate a treatment-related adverse event (TRAE). By the end of the treatment, ten participants experienced adverse events, and seven experienced TRAEs. However, none of the patients experienced any TRAEs higher than grade 3, and the researchers considered the drug 'well tolerated.' Most of the side effects were mild and included fever and issues where the drug was injected. Three participants had severe adverse events, but the researchers did not consider them TRAEs. One participant had to be hospitalized because of a urinary tract infection, and another had shortness of breath related to chronic heart failure. No serious dose-limiting toxicities occurred, and the participants' liver and platelet levels were stable throughout treatment. Additionally, cancer tumors shrank in six of the participants, and two participants went into complete remission. One of the participants who went into remission had melanoma, and the other had breast cancer. The researchers noted that not only did their tumors shrink, but tumors in the rest of the body disappeared. Wael Harb, MD, a board-certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers, spoke with Medical News Today and explained how the cancer drug works.'This drug (2141-V11) is an engineered antibody that flips a key 'ON' switch (CD40) on immune cells inside a tumor,' said Harb, who was not involved in the recent trial. 'It's injected directly into one tumor, where it organizes immune cells into mini lymph nodes called tertiary lymphoid structures (TLS).' 'Those act like on-site training camps that activate cancer-killing T-cells, which then travel through the body to attack tumors that weren't injected,' Harb he noted that the drug's safety profile was encouraging, he emphasized that larger trials are needed. 'Twelve patients are too few to draw firm safety conclusions across cancers–larger trials are needed and are already underway,' the oncologist is next for 2141-V11?Study author Juan Osorio, MD, director Of Clinical Operations And Translational Immunology at Rockefeller University, spoke with MNT and discussed the future of the research with 2141-V11. 'We look forward to the results of several ongoing phase 2 studies nationwide, targeting difficult-to-treat cancers, such as malignant gliomas, bladder cancer, and prostate cancer,' said Osorio. Osorio mentioned that early data from the phase 2 studies is 'promising,' but it is not a one-size-fits-all solution for people with cancer. 'Not all patients respond, highlighting the need for rational combination strategies to extend the benefit of this therapy,' Osorio shared. Osorio said the team is currently trying to figure out which biomarkers may predict response to CD40 agonists. 'Furthermore, we want to evaluate in larger cohorts whether TLS or other immune spatial interactions are crucial for effective induction of antitumor immunity. Answering these questions will be critical to fully translate this approach into meaningful and durable clinical benefit for patients.'

Researchers discover the immune system's ‘fountain of youth' - but it has a cost
Researchers discover the immune system's ‘fountain of youth' - but it has a cost

The Independent

timea day ago

  • The Independent

Researchers discover the immune system's ‘fountain of youth' - but it has a cost

Researchers have discovered the 'fountain of youth' for cells - but it comes with a big cost. Some people over 60 years old were found to have immune systems that appear to much younger in wear-and-tear, Mayo Clinic researchers announced Thursday. The immune system is what protects us from getting sick and promotes healing. With age, the immune system's ability to protect the body from infection and disease can wane. Young immune systems are constantly exposed to new bacteria and viruses, and previous research has shown that infant immune systems beat those of adults at fighting off the invaders. Researchers now say some have immune systems that don't match their age. "We observed that these patients have very young immune systems despite being in their 60s and 70s,' Dr. Cornelia Weyand, a Mayo Clinic rheumatologist and clinician-scientist, said in a statement. 'But the price they pay for that is autoimmunity.' Autoimmunity is what happens when the immune system mistakenly attacks healthy tissues and organs. There are more than 100 known autoimmune diseases, according to the Cleveland Clinic, including lupus, multiple sclerosis, psoriasis, celiac disease and Hashimoto's thyroiditis. Women are at a higher risk than men, thanks to genetic and hormonal differences, according to Stanford Medicine. Doctors discovered this anomaly in more than 100 older patients who went to the Minnesota clinic to receive treatment for a rare autoimmune disease known as giant cell arteritis. Giant cell arteritis is an inflammation of the lining of your arteries that can affect the arteries in your head, the clinic explained. Untreated, it can lead to blindness, an aortic aneurysm, and, less commonly, stroke. It frequently causes headaches, jaw pain and vision problems. What causes the disorder remains unknown. Studying the diseased tissue of these patients, the researchers found they had specialized cells in their immune system known as 'stem-like T cells.' The cells behave like young stem cells, which are critical for repairing and maintaining a healthy immune system. But, in this case, they were spreading the autoimmune disease. Going forward, the scientists hope to learn more about this link and what they observed from the patients. "Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body," Dr. Jörg Goronzy, a Mayo Clinic researcher on aging, said. "We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store